Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
Kenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, Keisuke Aiba, Kazuo Tamura, Keiko Iino, Chiyo K. Imamura, Kenji Okita, Yoshikazu Kagami, Ryuhei Tanaka, Kazuhiko Nakagawa, Hirofumi Fujii, Narikazu Boku, Makoto Wada, Tatsuo Akechi, Hirotoshi Iihara, Shoichiro Ohtani, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Yasuo Shima, Masayuki Takeda, Eijiro Nagasaki, Toshihiko Nishidate, Takahiro Higashi, Kouichi Hirata
Abstract
Patients with cancer should appropriately receive antiemetic therapies against chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an important role in managing CINV. Accordingly, the first Japanese antiemetic guideline published in 2010 by the Japan Society of Clinical Oncology (JSCO) has considerably aided Japanese medical staff in providing antiemetic therapies across chemotherapy clinics. With the yearly advancements in antiemetic therapies, the Japanese antiemetic guidelines require revisions according to published evidence regarding antiemetic management worldwide. A revised version of the first antiemetic guideline that considered several upcoming evidences had been published online in 2014 (version 1.2), in which several updated descriptions were included. The 2015 JSCO clinical practice guideline for antiemesis (version 2.0) (in Japanese) has addressed clinical antiemetic concerns and includes four major revisions regarding (1) changes in emetogenic risk categorization for anti-cancer agents, (2) olanzapine usage as an antiemetic drug, (3) the steroid-sparing method, and (4) adverse drug reactions of antiemetic agents. We herein present an English update summary for the 2015 JSCO clinical practice guideline for antiemesis (version 2.0).